<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596554</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0349</org_study_id>
    <secondary_id>2018-A01304-51</secondary_id>
    <nct_id>NCT03596554</nct_id>
  </id_info>
  <brief_title>X-linked Hypophosphatemia and FGF21</brief_title>
  <acronym>XLH 21</acronym>
  <official_title>X-linked Hypophosphatemia and Carbohydrate and Lipid Metabolism: a Role for FGF21?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroblast Growth Factor 23 and Fibroblast Growth Factor 21 are two endocrine Fibroblast
      Growth Factors, requiring Klotho as a co-factor to promote their systemic actions. Fibroblast
      Growth Factor 21 is involved in the regulation of glucid and lipid metabolism. Fibroblast
      Growth Factor 21 Knock Out mice display obesity and hyperglycemia.

      In investigators experience, patients with X-linked hypophosphatemia often present with
      early-onset over-weight that could be partly explained by decreased physical activity because
      of bone pains and deformations after puberty; however, patients usually display progressive
      over-weight earlier in life, when there is no limitation of physical activity yet.

      To the knowledge of investigators the association between Fibroblast Growth Factor 23,
      Fibroblast Growth Factor 21 and Klotho in patients with X-linked hypophosphatemia has never
      been evaluated. Thus, the main objective of this study is to evaluate the glucid and lipid
      metabolism in patients with X-linked hypophosphatemia, the main working hypothesis being that
      the genetic deregulation in the Fibroblast Growth Factor 23 axis in patients with X-linked
      hypophosphatemia induces modifications of Klotho levels (namely decreased levels) that in
      turn will deregulate the Fibroblast Growth Factor 21 axis (resistance to Fibroblast Growth
      Factor 21 because of decreased Klotho levels).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">January 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating FGF21</measure>
    <time_frame>1 day</time_frame>
    <description>Samples specific to the study will be collected during a sampling performed as part of the usual care and follow-up of the patient. An additional tube (5 ml maximum) will be collected, which will be sent to the Lyon Sud Hospital Center for analysis of circulating FGF21.</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>X-linked Hypophosphatemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Descriptive study</intervention_name>
    <description>Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 10 to 18 years followed in the different sites of the French Reference Center
        for Rare Diseases of Calcium and Phosphate, and monitored for hypophosphatemic rickets;
        estimated number to be included, N=40
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child with X-linked hypophosphatemia with PHEX gene mutation

          -  Child between 10 and 18 years old

          -  Child over 10 kg having a blood sample as part of the treatment (due to regulatory
             constraints for blood volume taken in 30-day period of 40 mL in children over 10 kg)

          -  Child and parent / holder of parental authority who has been informed of the study and
             does not object to participate.

        Exclusion Criteria:

        - Pregnancy in progress
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Justine BACCHETTA, Pr</last_name>
    <phone>04 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Rénales Rares - Centre de Référence des Maladies Rares du Calcium et du Phosphate - Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine BACCHETTA, Pr</last_name>
      <phone>04 27 85 61 30</phone>
      <phone_ext>+33</phone_ext>
      <email>justine.bacchetta@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélia BERTHOLET-THOMAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service d'Endocrinologie Pédiatrique - Hôpital du Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès LINGLART, Pr</last_name>
      <email>agnes.linglart@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anya ROTHENBUHLER, Dr</last_name>
      <email>anya.rothenbuhler@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Endocrinologie, Maladies Osseuses, Gynécologie, Génétique, Hôpital des Enfants, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Pierre SALLES, Pr</last_name>
      <email>salles.jp@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

